| Autor: |
R. Pencheva, J. Shabani, D. Trendafilova, J. Jorgova, H. Angelov, P. Simeonov, I. Dimitrova |
| Jazyk: |
Bulgarian<br />English |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Българска кардиология, Vol 28, Iss 2, Pp 102-110 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2683-1015 |
| DOI: |
10.3897/bgcardio.28.e82423 |
| Popis: |
In the modern days and the era of the rapid development of medical technology, the introduction of innovative invasive methods of treatment is gradually displacing traditional conventional surgery. In 2002 was performed the fi rst transcatheter implantation of an aortic valve. Over the next twenty years, with the advancement of technology and the accumulation of experience in clinical centers, transcatheter aortic valve implantation has become the standard in adult and high-risk patients with high-grade Ao stenosis. In a large percentage of cases enrolled under the transcatheter aortic valve protocol a concomitant ischemic heart disease is detected or known. Globally, there is no signifi cant difference in overall mortality on the thirtieth day after TAVI in patients with ischemic heart disease. However, the overall mortality was signifi cantly higher in one – year follow - up of patients after transcatheter aortic valve implantation with underlying coronary pathology. We conducted a study comparing the number of late and early adverse events in patients with concomitant fully revascularized ischemic heart disease and those with insignifi cant coronary atherosclerosis. Based on the data collected, analyzed and summarized in our clinical center, fully revascularized ischemic heart disease does not increase the percentage of major adverse events after transcatheter aortic valve implantation. It can be considered when assessing the risk of transcatheter aortic implantation, as part of the individual approach for each case. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
